Featured Job Post: Medical Director, Diabetes

Medical Director, Diabetes
Lexicon (Princeton, New Jersey)

Requisition #-130-252 Medical Director, Diabetes

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease located in The Woodlands, Texas and Princeton, New Jersey. We currently have multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by our world class research team. We have used our proprietary gene knockout technology to identify more than 100 promising drug targets. We focus drug discovery efforts on these biologically-validated targets to create our extensive pipeline of clinical and preclinical programs. Lexicon employees are inspired by the idea that their work can improve patients' lives and we know that our employees are important to the success of our mission. We are dedicated to making Lexicon a great place to work by providing employees with the benefits, services, and programs which will allow them to reach their full potential.

We are currently recruiting for a Medical Director for our Diabetes programs in our Woodlands, TX or Princeton NJ office.

United Healthcare, Aetna, and Kaiser Permanente

What do these 3 health plans have in common? United Healthcare, Aetna, and Kaiser Permanente

They now offer expanded coverage of continuous glucose monitors (CGM) for patients with type 1 diabetes. It's great to see advances in technology that have tangible impact on disease management.

Last month, the American Diabetes Association (ADA) published its 2009 Standards of Medical Care in Diabetes. The new standards recommends the use of CGM in the following ways:

• Continuous glucose monitoring (CGM) in conjunction with intensive insulin regimens can be a useful tool to lower A1C in selected adults (age ≥25 years) with type 1 diabetes.
• Although the evidence for A1C lowering is less strong in children, teens, and younger adults, CGM may be helpful in these groups. Success correlates with adherence to ongoing use of the device.
• CGM may be a supplemental tool to SMBG in those with hypoglycemia unawareness and/or frequent hypoglycemic episodes.

One of the studies that provided robust data on the use of CGM was this New England Journal of Medicine article:

The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group: Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 359:1464–1476, 2008